Lung Cancer
Volume 65, Issue 3 , Pages 284-289 , September 2009

Effect of gefitinib on N-nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J mice

Received 16 August 2008 ,Revised 26 November 2008 ,Accepted 27 November 2008.

References 

  1. Global cancer rates could increase by 50% to 15 million by 2020. http://www.who.int/mediacentre/news/releases/2003/pr27/en/.
  2. Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, et al., editors. SEER Cancer Statistics Review, 1975–2005, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2005/. Center for Cancer Control and Information Services, National Cancer Center, Japan http://ganjoho.ncc.go.jp/professional/statistics/statistics.html).
  3. Wang ZY, Hong JY, Huang MT, Reuhl KR, Conney AH, Yang CS. Inhibition of N-nitrosodiethylamine- and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced tumorigenesis in A/J mice by green tea and black tea. Cancer Res. 1992;52:1943–1947
  4. Mimoto J, Kiura K, Matsuo K, Yoshino T, Takata I, Ueoka H, et al. (−)-Epigallocatechin gallate can prevent cisplatin-induced lung tumorigenesis in A/J mice. Carcinogenesis. 2000;21:915–919
  5. Rioux N, Castonguay A. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res. 1998;58:5354–5360
  6. Saffiotti U, Montesano R, Sellakumar AR, Borg SA. Experimental cancer of the lung. Inhibition by vitamin A of the induction of tracheobronchial squamous metaplasia and squamous cell tumors. Cancer. 1967;20:857–864
  7. Willett WC, Polk BF, Underwood BA, Stampfer MJ, Pressel S, Rosner B, et al. Relation of serum vitamins A and E and carotenoids to the risk of cancer. N Engl J Med. 1984;310:430–434
  8. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994;330:1029–1035
  9. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression?. Oncologist. 2002;7(Suppl 4):31
  10. Dy GK, Adjei AA. Novel targets for lung cancer therapy. Part I. J Clin Oncol. 2002;20:2881–2894
  11. Abell CW, Falk HL, Shimkin MB, Weisburger EK, Weisburger JH, Gubareff N. Uracil mustard: a potent inducer of lung tumors in mice. Science. 1965;147:1443–1445
  12. Hecht SS, Isaacs S, Trushin N. Lung tumor induction in A/J mice by the tobacco smoke carcinogens 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and benzo[a]pyrene: a potentially useful model for evaluation of chemopreventive agents. Carcinogenesis. 1994;15:2721–2725
  13. Langenfeld J, Lonardo F, Kiyokawa H, Passalaris T, Ahn MJ, Rusch V, et al. Inhibited transformation of immortalized human bronchial epithelial cells by retinoic acid is linked to cyclin E down-regulation. Oncogene. 1996;13:1983–1990
  14. Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 1993;53(suppl. 10):2379–2385
  15. Lonardo F, Dragnev KH, Freemantle SJ, Ma Y, Memoli N, Sekula D, et al. Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. Clin Cancer Res. 2002;8:54–60
  16. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol. 2002;20:110
  17. Gefitinib Iressa 250mg Tablet No. 28 New Drug Approval Package (NAP) Japan Pharmaceutical Education Center, Yakuji Nipposha, Tokyo, Japan; 2003.
  18. Leopold WR, Batzinger RP, Miller EC, Miller JA, Earhart RH. Mutagenicity, tumorigenicity, and electrophilic reactivity of the stereoisomeric platinum(II) complexes of 1,2-diaminocyclohexane. Cancer Res. 1981;41(11 Pt 1):4368–4377
  19. Hisamoto A, Kondo E, Kiura K, Okada T, Hosokawa S, Mimoto J, et al. Point mutation of K-ras gene in cisplatin-induced lung tumours in A/J mice. Lung Cancer. 2007;58:15–20
  20. Belinsky SA, Devereux TR, Maronpot RR, Stoner GD, Anderson MW. Relationship between the formation of promutagenic adducts and the activation of the K-ras protooncogene in lung tumors from A/J mice treated with nitrosamines. Cancer Res. 1989;49:5305–5311
  21. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–1500
  22. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–2139
  23. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306–13311
  24. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004;64:8919–8923
  25. Kitahashi T, Takahashi M, Yamada Y, Oghiso Y, Yokohira M, Imaida K, et al. Occurrence of mutations in the epidermal growth factor receptor gene in X-ray-induced rat lung tumors. Cancer Sci. 2008;99:241–245
  26. Uchida A, Hirano S, Kitao H, Ogino A, Rai K, Toyooka S, et al. Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation. Cancer Sci. 2007;98:357–363
  27. Yan Y, Lu Y, Wang M, Vikis H, Yao R, Wang Y, et al. Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer. Mol Cancer Res. 2006;4:971–981
  28. Suzuki H, Aoshiba K, Yokohori N, Nagai A. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res. 2003;63:5054–5059
  29. Ishii Y, Fujimoto S, Fukuda T. Gefitinib prevents bleomycin-induced lung fibrosis in mice. Am J Respir Crit Care Med. 2006;174:550–556
  30. Igarashi M, Yoshida M, Watanabe M, Abe M, Sugano S, Nakae D. Lung carcinogenesis induced by NNK in Ogg1 knockout mice. Proceedings of the 66th Annual Meeting of the Japanese Cancer Association. 2007.

PII: S0169-5002(08)00622-3

doi: 10.1016/j.lungcan.2008.11.021

Lung Cancer
Volume 65, Issue 3 , Pages 284-289 , September 2009

Article Tools

* Image Usage & Resolution